“Resistance to Pembrolizumab and Axitinib in Renal Cell Carcinoma: Clinical and Genomic Evaluation”, jkcvhl, vol. 7, no. 1, pp. 7–11, Jun. 2020, doi: 10.15586/jkcvhl.2020.135.